Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity.
- Resource Type
- Article
- Source
- RMD Open; Dec2022, Vol. 8 Issue 2, p1-3, 3p
- Subject
- Language
- ISSN
- 20565933